Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Net Income: 2020-2024

Historic Net Income for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$41.9 million.

  • SAB Biotherapeutics' Net Income fell 16.60% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 6.57%. This contributed to the annual value of -$41.9 million for FY2024, which is 0.59% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Net Income stood at -$41.9 million for FY2024, which was up 0.59% from -$42.2 million recorded in FY2023.
  • SAB Biotherapeutics' Net Income's 5-year high stood at $20.1 million during FY2020, with a 5-year trough of -$42.2 million in FY2023.
  • For the 3-year period, SAB Biotherapeutics' Net Income averaged around -$34.3 million, with its median value being -$41.9 million (2024).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 185.24% in 2021, then climbed by 0.59% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Net Income (Yearly) stood at $20.1 million in 2020, then crashed by 185.24% to -$17.1 million in 2021, then fell by 9.31% to -$18.7 million in 2022, then slumped by 125.14% to -$42.2 million in 2023, then rose by 0.59% to -$41.9 million in 2024.